Nasdaq:US$15.44 (+0.12) | HKEX:HK$24.34 (+0.02) | AIM:£2.24 (-0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor